In patients with early breast cancer, personal and tumour characteristics other than family history are increasingly used to prompt genetic testing to guide women’s cancer management (treatment-focused genetic testing, ‘TFGT’). Women without a known strong family history of breast and/or ovarian may be more vulnerable to psychological sequelae arising from TFGT. We compared the impact of TFGT in women with (FH+) and without (FH−) a strong family history on psychological adjustment and surgical decisions. Women aged <50 years with high-risk features were offered TFGT before definitive breast cancer surgery and completed self-report questionnaires at four time points over 12 months. All 128 women opted for TFGT. TFGT identified 18 carriers of a disease-causing variant (50.0% FH+) and 110 non-carriers (59.1% FH+). There were no differences based on family history in bilateral mastectomy (BM) uptake, p = .190, or uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO), p = .093. FH− women had lower decreases in anxiety a year after diagnosis, p = .011, and regret regarding their decision whether to undergo BM, p = .022, or RRBSO, p = .016 than FH + women. FH− carriers reported significantly higher regret regarding their TFGT choice (p = .024) and test-related distress (p = .012) than FH + carriers, but this regret/distress could not be attributed to a concern regarding a possible worse prognosis. These findings indicate that FH− women may require additional counselling to facilitate informed decisions. Carriers without a family history may require additional follow-up counselling to facilitate psychological adjustment to their positive variant results, extra support in making surgical decisions, and counselling about how best to communicate results to family members.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $92.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We thank the patients who generously participated in this study. We also gratefully acknowledge the assistance of the staff who were involved at each site. Thank you also to Mariana Souza for research assistance. We also acknowledge the support and endorsement of this project by the Psycho-oncology Cooperative Research Group (PoCoG). This trial was funded by a Priority-Driven Collaborative Research Grant, which was jointly supported by Cancer Australia, Cancer Council Australia and the National Breast Cancer Foundation (ID 630405). Bettina Meiser was supported by a Career Development Fellowship Award Level 2 (ID 1003921) from the National Health and Medical Research Council (NHMRC) of Australia and an NHMRC Senior Research Fellowship Level B (ID 1078523). Michelle Peate is currently supported by a National Breast Cancer Foundation Early Career Fellowship (ECF-15-005).
TFGT Collaborative Group
The additional members of the Treatment FocusedGenetic Testing Collaborative Group are: Cabrini Health Melbourne (P. Gregory, L.Lipton, L. McKay, J. Senior); Department of Medical Oncology, Prince of WalesHospital (P. Crowe, A. Matthews, G. Neil, A. Parasyn, D. Thomson); HereditaryCancer Clinic, Prince of Wales Hospital, Sydney (J. Duffy, L. Andrews, J. Gale);Monash Medical Centre, Melbourne (J. Fox, S. Hart, C. Smythe, M. White);Nambour Hospital, Nambour (L. Creighton, J. D’arcy, S. Grieve, E. Secomb); PeterMacCallum Cancer Centre, Melbourne (M. Henderson, J. O’Brien, C. Poliness);Royal Brisbane Hospital (A. Hattam, R. Susman, O. Ung,); Royal North ShoreHospital, Sydney (R. Dickson, K. Moore); St George Hospital, Sydney (P. Bastick, S.Inder, J. Lynch, P. Schwartz, R. Zia); The Poche Centre, Sydney (C. Mak, K. Snook,A. Spillane); University of Melbourne (J. Hopper); Westmead Hospital, Sydney (M.Bowman, D. Cheung, S. Edirimanne, E. Edwards, E. Elder, J. French, D. Moon).